Trends of cutaneous melanoma in The Netherlands: increasing incidence rates among all Breslow thickness categories and rising mortality rates since 1989.

BACKGROUND It has been debated that the epidemic of melanoma is largely due to overdiagnosis, since increases in incidence were mainly among thin melanomas and mortality rates remained stable. Our objective was to examine this controversy in The Netherlands. PATIENTS AND METHODS Information on newly diagnosed melanoma patients was obtained from The Netherlands Cancer Registry. European Standardized Rates and estimated annual percentage change were calculated for the period 1989-2008. Cohort-based, period-based and multivariate survival analyses were carried out. RESULTS The incidence rate of melanoma increased with 4.1% (95% confidence interval 3.6-4.5) annually. Incidence rates of both thin melanomas (≤ 1 mm) and thick melanomas (> 4 mm) increased since 1989. Mortality rates increased mainly in older patients (> 65 years). Ten-year relative survival of males improved significantly from 70% in 1989-1993 to 77% in 2004-2008 (P < 0.001) and for females the 10-year relative survival increased from 85% to 88% (P < 0.01). Recently diagnosed patients had a better prognosis even after adjusting for all known prognostic factors. CONCLUSION Since incidence of melanomas among all Breslow thickness categories increased as well as the mortality rates, the melanoma epidemic in The Netherlands seems to be real and not only due to overdiagnosis.

[1]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[2]  M. Lens,et al.  Sentinel lymph node biopsy in melanoma patients , 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  A. Izquierdo,et al.  Rising trends in incidence of cutaneous malignant melanoma and their future projections in Catalonia, Spain: increasing impact or future epidemic? , 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[5]  Esther de Vries,et al.  Incidence and trends of cutaneous malignancies in the Netherlands, 1989-2005. , 2010, The Journal of investigative dermatology.

[6]  H. Welch,et al.  Overdiagnosis in cancer. , 2010, Journal of the National Cancer Institute.

[7]  M. Driscoll,et al.  Melanoma epidemic: Facts and controversies. , 2010, Clinics in dermatology.

[8]  L. Kiemeney,et al.  Explanations for worsening cancer survival , 2010, Nature Reviews Clinical Oncology.

[9]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Gavin,et al.  Cutaneous melanoma mortality starting to change: a study of trends in Northern Ireland. , 2009, European journal of cancer.

[11]  D. Greenberg,et al.  Melanoma epidemic: a midsummer night’s dream? , 2009, The British journal of dermatology.

[12]  Z. Nugent,et al.  Incidence and anatomic presentation of cutaneous malignant melanoma in central Canada during a 50-year period: 1956 to 2005. , 2009, Journal of the American Academy of Dermatology.

[13]  Myles G Cockburn,et al.  Increasing burden of melanoma in the United States. , 2009, The Journal of investigative dermatology.

[14]  V. del Marmol,et al.  A Prime minister managed to attract elderly men in a Belgian Euromelanoma campaign. , 2009, European journal of cancer.

[15]  Michael Schmidt,et al.  Time trends in tumour thickness vary in subgroups: analysis of 6475 patients by age, tumour site and melanoma subtype , 2009, Melanoma research.

[16]  D. Forman,et al.  Trends in prognostic factors and survival from cutaneous melanoma in Yorkshire, UK and New South Wales, Australia between 1993 and 2003 , 2008, International journal of cancer.

[17]  Sabine Siesling,et al.  Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. , 2008, European journal of cancer.

[18]  V. Siskind,et al.  Changes in the incidence of cutaneous melanoma in the west of Scotland and Queensland, Australia: hope for health promotion? , 2008, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[19]  M. Janssen-Heijnen,et al.  Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  S. O’Day,et al.  Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4) , 2007, Cancer.

[21]  M. Janssen-Heijnen,et al.  Up-to-date survival estimates and historical trends of cutaneous malignant melanoma in the south-east of The Netherlands. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  P. Carli,et al.  The melanoma epidemic debate: some evidence for a real phenomenon from Tuscany, Italy , 2007, Melanoma research.

[23]  D. Forman,et al.  Recent trends in cutaneous malignant melanoma in the Yorkshire region of England; incidence, mortality and survival in relation to stage of disease, 1993–2003 , 2006, British Journal of Cancer.

[24]  Lisa M. Schwartz,et al.  Skin biopsy rates and incidence of melanoma: population based ecological study , 2005, BMJ : British Medical Journal.

[25]  F. D. de Gruijl,et al.  Predictions of skin cancer incidence in the Netherlands up to 2015 , 2005, The British journal of dermatology.

[26]  Paul W Dickman,et al.  Regression models for relative survival , 2004, Statistics in medicine.

[27]  A. Eggermont,et al.  Rising trends in the incidence of and mortality from cutaneous melanoma in the Netherlands: a Northwest to Southeast gradient? , 2003, European journal of cancer.

[28]  M. Nicolson,et al.  Incidence of and survival from malignant melanoma in Scotland: an epidemiological study , 2002, The Lancet.

[29]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[30]  D. Reintgen,et al.  The Progression of Melanoma Nodal Metastasis Is Dependent on Tumor Thickness of the Primary Lesion , 1999, Annals of Surgical Oncology.

[31]  O. Gefeller,et al.  An alternative approach to monitoring cancer patient survival. , 1996, Cancer.

[32]  H Straatman,et al.  The capture-recapture method for estimation of cancer registry completeness: a useful tool? , 1994, International journal of epidemiology.

[33]  H. J. V. D. Rhee,et al.  De 'sproetenbus'; een ongezond verschijnsel of een bezonnen experiment? , 1990 .

[34]  K. Welvaart,et al.  [The 'freckle bus' campaign; an unhealthy phenomenon or a sensible experiment?]. , 1990, Nederlandsch tijdschrift voor geneeskunde.

[35]  R. Doll Cancer in Five Continents , 1972, Proceedings of the Royal Society of Medicine.